Table 2.
Characteristics of the patients at inclusion (n=247).
| Characteristics | WAPa only (n=123) | DAPb+WAP (n=124) | |||||
|
|
Children aged 6 to 18 years (n=45) | Adults (n=78) | Children aged 6 to 18 years (n=48) | Adults (n=76) | |||
| Sex, n (%) | |||||||
|
|
Female | 21 (47) | 56 (72) | 18 (38) | 59 (78) | ||
|
|
Male | 24 (53) | 22 (28) | 30 (62) | 17 (22) | ||
| Age (years), mean (SD) | 8.3 (2.0) | 36.3 (12.7) | 9.0 (1.9) | 34.5 (11.3) | |||
| Height (cm), mean (SD) | 133.2 (11.7) | 166.1 (9.9) | 136.7 (12.7) | 164.5 (8.3) | |||
| Weight (kg), mean (SD) | 30.9 (9.5) | 69.9 (19.0) | 33.5 (11.2) | 71.1 (18.5) | |||
| BMI (kg/m2), mean (SD) | 17.18 (2.97) | 25.32 (6.18) | 17.35 (2.91) | 26.25 (6.77) | |||
| Age at asthma diagnosis (years), median (IQR) | 5.0 (3.0-7.0) | 12.0 (5.0-24.0) | 4.0 (2.0-7.0) | 16.0 (4.0-30.0) | |||
| Atopyc, n/N (%) tested | 25/38 (66) | 54/72 (75) | 30/42 (71) | 50/69 (72) | |||
| Diagnosed with atopic dermatitis at least once, n (%) | 9 (20) | 23 (29) | 12 (25) | 21 (28) | |||
| Diagnosed with rhinitis at least once, n (%) | 28 (62) | 60 (77) | 31 (65) | 54 (71) | |||
| Diagnosed with conjunctivitis at least once, n (%) | 14 (31) | 34 (44) | 8 (17) | 34 (45) | |||
| Smoking history, n (%) | |||||||
|
|
Never | —d | 51 (65) | — | 45 (56) | ||
|
|
Former | — | 16 (21) | — | 15 (20) | ||
|
|
Current | — | 11 (14) | — | 16 (21) | ||
|
|
Passive tobacco smoke exposure | 14 (31) | — | 20 (42) | — | ||
| Severe exacerbations in the past year, n | 76 | 194 | 74 | 144 | |||
| Admission for exacerbation in the past year, n (%) | 21 (47) | 19 (24) | 21 (44) | 35 (46) | |||
| Previous therapeutic education, n (%) | 2 (4) | 8 (10) | 1 (2) | 5 (7) | |||
| GINAe asthma control score last month, median (IQR) | 1.0 (0.0-2.0) | 3.0 (1.0-4.0) | 1.0 (0.0-3.0) | 3.0 (1.0-4.0) | |||
| Control, n (%) | |||||||
|
|
Optimal | 16 (36) | 16 (21) | 15 (31) | 15 (20) | ||
|
|
Partial | 18 (40) | 21 (27) | 20 (42) | 17 (22) | ||
|
|
Uncontrolled | 11 (24) | 41 (53) | 13 (27) | 44 (58) | ||
| Asthma treatment, n (%) | |||||||
|
|
Adherence | ||||||
|
|
|
Good | 20 (44) | 54 (69) | 23 (48) | 47 (62) | |
|
|
|
Moderate | 5 (11) | 20 (26) | 4 (8) | 23 (30) | |
|
|
|
Nil | 0 (0) | 2 (3) | 1 (2) | 1 (1) | |
|
|
|
Missingf | 20 (44) | 2 (3) | 20 (42) | 5 (7) | |
|
|
Spacer device | 30 (67) | 1 (1) | 31 (65) | 3 (4) | ||
|
|
Inhaled corticosteroid | 19 (42) | 4 (5) | 17 (35) | 4 (5) | ||
|
|
Inhaled corticosteroid plus LAg β-adrenergic | 19 (42) | 73 (94) | 22 (46) | 72 (95) | ||
|
|
Ipratropium | 0 (0) | 9 (12) | 0 (0) | 3 (4) | ||
|
|
Montelukast | 1 (2) | 23 (29) | 3 (6) | 16 (21) | ||
|
|
Omalizumab | 0 (0) | 3 (4) | 0 (0) | 2 (3) | ||
aWAP: written action plan.
bDAP: digital action plan.
cDefined as at least 1 positive skin-prick test or high antiaeroallergen immunoglobulin E titer.
dNot recorded.
eGINA: Global Initiative for Asthma.
fReported by the participant or parents at the inclusion visit.
gLA: long-acting.